This new, blood-based test successfully identifies individuals with lymph node metastasis associated with high-risk T1 colorectal cancer and potentially could help people with non-high-risk ...
Scientists at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, have developed a novel, noninvasive liquid biopsy test for detecting lymph node ...
A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes—a finding that could guide treatment ...
SAN ANTONIO, Dec. 18 /PRNewswire/ -- Results from a prospective clinical study show that the GeneSearch(TM) Breast Lymph Node (BLN) Assay, a gene-based diagnostic test has greater sensitivity than ...
Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...
Scientists at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, have developed a novel, noninvasive liquid biopsy test for detecting lymph node ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results